TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04162821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: Take hydroxynitone capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: Take hydroxynitone capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: Take hydroxynitone capsule
Study: NCT03478514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Taken at 100 mg once daily for 21 days, followed by 7 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg taken orally all patients throughout the study
Study: NCT03870984

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wNUTS, low-caloric diet plus nuts
Description: 15g of nuts and 15g of hazelnuts in association with low caloric diet

Intervention type: OTHER
Group type: OTHER
Intervention: w/oNUTS, low-caloric diet without nuts
Description: low caloric diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: w/oNUTS, low-caloric diet without nuts
Description: low caloric diet
Study: NCT02671357

Intervention type: PROCEDURE
Intervention: ERAMIP
Description: 3D-LPD with stented umbrella-pancreaticogastrostomy \& Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
Study: NCT02916849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe Step
Description: Strength and balance exercise-digital version

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe Step
Description: Strength and balance exercise-digital version

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe Step
Description: Strength and balance exercise-digital version

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OEP
Description: Strength and balance exercise -paper version

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OEP
Description: Strength and balance exercise -paper version
Study: NCT00349375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/Simvastatin
Description: Combination of Fenofibrate 145mg and Simvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/Simvastatin
Description: Combination of Fenofibrate and Simvastatin 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg
Study: NCT04507542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched Music-Supported Therapy
Description: Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program is based on musical training, combining self-training sessions of music playing using an app for electronic tablets and music therapy group sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Graded Repetitive Arm Supplementary Program
Description: Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program comprises self-training sessions of mass repetition of movements and task-specific exercises for the upper extremity.
Study: NCT03427047

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyKnee with single use Efficiency Instrument
Description: Total Knee Arthroplasty utilizing a CT scan for customization of cutting blocks with single use instrumentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Navigational with conventional metal instruments
Description: Total Knee Arthroplasty without customization of cutting blocks using conventional metal instruments.
Study: NCT01454375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to QuitNow Services
Description: QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
Study: NCT02182752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Interscalene block using ropivacaine
Study: NCT01980537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic wire navigation
Study: NCT01987206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPC control algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PID control algorithm
Study: NCT00767052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: 75mg once daily or 75mg twice daily will be administered in multiple dose part.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching to the active in multiple dose part.

Intervention type: DRUG
Group type: OTHER
Intervention: AZD1236
Description: 75mg single dose will be administered in relative bioavailability part.

Intervention type: DRUG
Group type: OTHER
Intervention: AZD1236
Description: 75mg oral suspension single dose will be administered in relative bioavailability part.
Study: NCT03059238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled-release oxycodone
Study: NCT01863940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound Catheter
Description: Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
Study: NCT04876170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain-computer-interface: EEG-based musical Neurofeedback task
Description: Neurofeedback training with EEG, in which participants are presented with self-selected music and requested to make the presented music sound better by applying mental strategies. Six repeated training sessions, each composed of five training cycles. Each cycle is composed of 120 sec of 'local baseline' block and 90 sec of 'regulation' block while listening to self-selected music. Participants are instructed to passively listen to their self-selected music during the 'local baseline' block, and to 'make the music sound better' during the 'regulation' block. Participants are instructed to recruit chosen mental strategies, which they find to be most efficient towards this regulatory task. During 'regulation', the quality of the sound varies in real-time (every 3 sec) in proportion to the difference between the current value of VS-EFP and its average value during 'local baseline'.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain-computer-interface: EEG-based musical Neurofeedback task
Description: Neurofeedback training with EEG, in which participants are presented with self-selected music and requested to make the presented music sound better by applying mental strategies. Six repeated training sessions, each composed of five training cycles. Each cycle is composed of 120 sec of 'local baseline' block and 90 sec of 'regulation' block while listening to self-selected music. Participants are instructed to passively listen to their self-selected music during the 'local baseline' block, and to 'make the music sound better' during the 'regulation' block. Participants are instructed to recruit chosen mental strategies, which they find to be most efficient towards this regulatory task. During 'regulation', the quality of the sound varies in real-time (every 3 sec) in proportion to the difference between the current value of VS-EFP and its average value during 'local baseline'.
Study: NCT04268251

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI with deep learning based denoising
Description: 1-mm coronal contrast-enhanced T1 weighted image with deep learning based denoising
Study: NCT01497470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custirsen, paclitaxel and carboplatin
Description: Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
Study: NCT00483561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib plus etoposide
Description: Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
Study: NCT04161820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke
Description: The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later.
Study: NCT03471039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACAP27
Description: Infusion of PACAP27 over 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of Saline over 20 minutes.
Study: NCT01739985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone + ondansetron + Placebo
Description: Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone + ondansetron + Droperidol
Description: Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
Study: NCT00634634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
Study: NCT02110368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Topical Gel, 1.62% Metered Pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Study: NCT00675922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamylon 5% and Silver Nitrate Soaks
Description: Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
Study: NCT03581227

Intervention type: OTHER
Intervention: CAPTURE Tool
Description: CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
Study: NCT03723707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EQUIPED-ADRD Intervention
Description: (10 clinic sites and \~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control (CON)
Description: Will use current guidelines for primary care treatment with Diabetes and Dementia
Study: NCT03711656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: isCGM (intermittently scanned Continuous Glucose Monitoring)
Description: Data collection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical exercise tracker
Description: Data collection
Study: NCT01847482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZOLL Intravascular Temperature Management System (IVTM)
Description: Induced therapeutic hypothermia post cardiac arrest
Study: NCT03700281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messaging
Description: The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messaging
Description: The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
Study: NCT02995486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
Study: NCT03886753

Intervention type: OTHER
Intervention: Registry
Description: Collect data on subjects

Intervention type: OTHER
Intervention: Registry
Description: Collect data on subjects

Intervention type: OTHER
Intervention: Registry
Description: Collect data on subjects

Intervention type: OTHER
Intervention: Registry
Description: Collect data on subjects

Intervention type: OTHER
Intervention: PK microsampling of blood
Description: Obtain 5 microsamples of blood from subjects via a fingerstick.

Intervention type: OTHER
Intervention: PK microsampling of blood
Description: Obtain 5 microsamples of blood from subjects via a fingerstick.

Intervention type: OTHER
Intervention: PK microsampling of blood
Description: Obtain 5 microsamples of blood from subjects via a fingerstick.

Intervention type: OTHER
Intervention: PK microsampling of blood
Description: Obtain 5 microsamples of blood from subjects via a fingerstick.
Study: NCT04238975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3111 vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix® vaccine
Description: 0.5mL, Intramuscular
Study: NCT03317041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capacitive-resistive electric transfer (Tecar) therapy
Description: The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
Study: NCT01586884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure/Conductance Catheter
Description: The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.~The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.~The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point.
Study: NCT01439464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4 CIS one-touch titanium cage
Description: 4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonglass-SS SSLPB
Description: Bonglass-SS SSLPB(BioAlpha Inc.)
Study: NCT01838616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged Release
Description: All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Naloxone Prolonged Release
Description: All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
Study: NCT04340375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP green tea extracts
Description: AP green tea extracts
Study: NCT00838773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YMSM
Description: Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YHA
Description: Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROMA
Description: Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
Study: NCT01035385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOFLOX4
Description: FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
Study: NCT00514514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: 1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: 1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandimmun Optoral
Description: 1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmun Optoral
Description: 1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmun Optoral
Description: 1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect®
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
Study: NCT02288936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg/day
Study: NCT00428909

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib/Acetaminophen
Study: NCT02471703

Intervention type: DEVICE
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty
Study: NCT01424111

Intervention type: DRUG
Intervention: Escitalopram
Description: An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.

Intervention type: OTHER
Intervention: Healthy Control
Description: No Treatment
Study: NCT03332498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 milligrams of pembrolizumab will be given through an IV (intravenously) for about thirty minutes. Pembrolizumab is an anti-PD1 that functions by inhibiting checkpoint inhibition and reversing T cell suppression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib oral capsules every day starting on cycle 1, day 1. Ibrutinib is primarily a BTK inhibitor which has been approved for the treatment of several hematologic malignancies.